
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines, a biotechnology company focused on oncology, reported a significant increase in core drug Brukinsa's sales, rising 105% year-over-year to US$2.6 billion, which constitutes 68% of its total revenue for 2024, indicating robust market demand and revenue generation. Furthermore, Tevimbra's sales also experienced a positive shift, increasing 16% year-over-year to US$621 million, outperforming a key competitor, highlighting BeOne's competitive edge in the oncology market. The company ended 2024 with US$2.6 billion in cash, providing a strong liquidity position that supports future growth and expansion initiatives within the industry.
Bears say
BeiGene's financial outlook remains negative primarily due to a substantial decrease in cash flow from operations, which fell from US$188 million in the third quarter to US$75 million in the fourth quarter of 2024, driven by increased receivables and inventory levels. The company also reported a net loss of US$645 million, albeit a 27% reduction year-over-year, indicating persistent financial challenges despite some improvement. Additionally, revised market share estimates and peak sales projections for key products, particularly in light of the struggles within the TIGIT class of drugs, further contribute to concerns about BeiGene's revenue prospects moving forward.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares